G
GenAssist Therapeutics
Develops gene therapy drugs using base editing technology
About GenAssist Therapeutics
GenAssist Therapeutics, established in Suzhou, China, in July 2020, is a clinical-stage biotechnology firm focused on developing gene-editing therapies for genetic diseases. The company was co-founded by Dr. Chunyan He (CEO) and Dr. Xing Chang (Chief Scientific Advisor). Dr. He brings extensive experience in viral product development and business incubation, while Dr. Chang is a scientist from Westlake University recognized as a pioneer in the research and application of base editing technology in China, particularly for muscle-related diseases.
The company's core technology is a proprietary base editing platform known as Targeted AID-based Mutagenesis (TAM), for which it holds global rights. This technology aims to precisely repair disease-causing gene mutations in situ, offering the potential for a permanent cure. GenAssist's primary business involves the research and development of these novel gene-editing drugs, with a business model centered on advancing its product pipeline through clinical trials and eventual commercialization. The company operates through its main entity in Suzhou and has subsidiaries in Shanghai and Boston, USA.
The lead product candidate, GEN6050X, is a base editing drug developed to treat Duchenne Muscular Dystrophy (DMD), a rare genetic disorder that causes progressive muscle degeneration and weakness. DMD affects approximately one in every 3,500-5,000 newborn boys and currently lacks effective treatments. GEN6050X is designed for patients amenable to exon 50 skipping and is administered intravenously via a dual AAV9 vector system. The goal is to permanently restore the production of the essential dystrophin protein with a single treatment. In March 2025, GenAssist received Investigational New Drug (IND) clearance from the U.S. FDA for GEN6050X, marking it as a significant milestone for a gene editing therapy for DMD. An investigator-initiated trial for GEN6050X began in September 2024, with the first patient being dosed.
Since its inception, GenAssist has secured significant funding to advance its research. A pre-Series A round in July 2021 was led by Sequoia Capital China Fund, and a Series A round in December 2022 was led by the AstraZeneca-CICC Healthcare Industry Fund, with participation from Baidu Ventures and others. These funds are allocated to advancing preclinical studies, IND applications, and clinical trials for its therapeutic pipeline.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Dec 2022 | $20M | $80M | AZ-CICC Healthcare Investment Fund | ↗ |
| SEEDEquity / VC | Dec 2020 | $0 | — | Redhill Capital | ↗ |
Growth signals
Latest recorded traffic for GenAssist Therapeutics is 1.4K monthly website visits, down 6.7% over the last three months. GenAssist Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
GenAssist Therapeutics in the Suzhou Shi ecosystem
The GenAssist Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
- RCRedhill Capital
Series A1 investor entered at this stage
- AFAZ-CICC Healthcare Investment Fund
Other known investors2 additional known investors
Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences
Westlake University
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about GenAssist Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See GenAssist Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










